A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuz...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Huiping Li, Jiang Liu, Jianing Chen, Huiyun Wang, Linbin Yang, Fei Chen, Siting Fan, Jing Wang, Bin Shao, Dong Yin, Musheng Zeng, Mengfeng Li, Jun Li, Fengxi Su, Qiang Liu, Herui Yao, Shicheng Su, Erwei Song
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/3dad2bae89b54a468c806a881fe5461a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3dad2bae89b54a468c806a881fe5461a
record_format dspace
spelling oai:doaj.org-article:3dad2bae89b54a468c806a881fe5461a2021-12-02T17:32:34ZA serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients10.1038/s41467-018-03537-w2041-1723https://doaj.org/article/3dad2bae89b54a468c806a881fe5461a2018-04-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-03537-whttps://doaj.org/toc/2041-1723Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuzumab.Huiping LiJiang LiuJianing ChenHuiyun WangLinbin YangFei ChenSiting FanJing WangBin ShaoDong YinMusheng ZengMengfeng LiJun LiFengxi SuQiang LiuHerui YaoShicheng SuErwei SongNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Huiping Li
Jiang Liu
Jianing Chen
Huiyun Wang
Linbin Yang
Fei Chen
Siting Fan
Jing Wang
Bin Shao
Dong Yin
Musheng Zeng
Mengfeng Li
Jun Li
Fengxi Su
Qiang Liu
Herui Yao
Shicheng Su
Erwei Song
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
description Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuzumab.
format article
author Huiping Li
Jiang Liu
Jianing Chen
Huiyun Wang
Linbin Yang
Fei Chen
Siting Fan
Jing Wang
Bin Shao
Dong Yin
Musheng Zeng
Mengfeng Li
Jun Li
Fengxi Su
Qiang Liu
Herui Yao
Shicheng Su
Erwei Song
author_facet Huiping Li
Jiang Liu
Jianing Chen
Huiyun Wang
Linbin Yang
Fei Chen
Siting Fan
Jing Wang
Bin Shao
Dong Yin
Musheng Zeng
Mengfeng Li
Jun Li
Fengxi Su
Qiang Liu
Herui Yao
Shicheng Su
Erwei Song
author_sort Huiping Li
title A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
title_short A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
title_full A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
title_fullStr A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
title_full_unstemmed A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
title_sort serum microrna signature predicts trastuzumab benefit in her2-positive metastatic breast cancer patients
publisher Nature Portfolio
publishDate 2018
url https://doaj.org/article/3dad2bae89b54a468c806a881fe5461a
work_keys_str_mv AT huipingli aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jiangliu aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jianingchen aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT huiyunwang aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT linbinyang aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT feichen aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT sitingfan aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jingwang aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT binshao aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT dongyin aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT mushengzeng aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT mengfengli aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT junli aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT fengxisu aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT qiangliu aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT heruiyao aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT shichengsu aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT erweisong aserummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT huipingli serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jiangliu serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jianingchen serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT huiyunwang serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT linbinyang serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT feichen serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT sitingfan serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT jingwang serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT binshao serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT dongyin serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT mushengzeng serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT mengfengli serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT junli serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT fengxisu serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT qiangliu serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT heruiyao serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT shichengsu serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
AT erweisong serummicrornasignaturepredictstrastuzumabbenefitinher2positivemetastaticbreastcancerpatients
_version_ 1718380242990530560

Ejemplares similares